8 Vital Skills Your Organization Needs To Flourish In Digital Therapeutics
Market researchers state the current value of the globaldigital therapeutics market is >$4.2 billion . It’s not only significantly valuable; it’s also one of the fastest-growing industries worldwide.
The market’s growth trends upward as people are increasingly comfortable using apps and digital products to improve their health.
Moreover, the rapid evolution of computing, sensing, imaging, and analytics technology makes digital therapeutics—or, DTx—both more effective and less expensive with each passing season.
But, that doesn’t mean every DTx investment is wise. To pursue DTx effectively, it’s critical to understand the current landscape in detail.
This lets healthcare industry leaders predict which DTx options will thrive, given the technological, cultural, and legal changes that will likely come to pass in the next few decades.
Digital Therapeutics vs. Digital Health: What is the Future of Digital Care?
Digital health is a broad term for any software application, medical technology, or internet-connected device that aims to help people treat or manage their health.
Within the realm of digital health, digital therapeutics (DTx) is a category of technology that aids the diagnosis and treatment of specific illnesses and conditions.
While some digital health products are widely available, prescription digital therapeutics must meet FDA standards. DTx technology must demonstrate it effectively diagnoses or treats a condition in a clinical trial.
The future of the DTx market is bright. But, like many medical devices is fate hinges on the outcomes of clinical trials. This piece examines the current, near-future, and far-future focus on the DTx market as a whole.
DTx Market Focus: Safety, Efficacy, Cost-Effectiveness
Currently, the digital therapeutic technology market is focused on improving efficacy and safety while reducing costs. Four technological channels currently stand out by these metrics:
- Artificial intelligence (AI)
- Clinical decision support
- Smart medical devices and implants
- Gamified and virtual reality (VR) therapies
In addition to technological avenues, the DTx market is shaped by new and proposed regulations and processes. It may also shift in response to calls for accelerated clinical trials.
Recently, the Department of Justice began investigating Cerebral, a telehealth startup. They focused on prescribing medications for mental illnesses.
But, it allegedly enabled widespread, inappropriate prescriptions and misdiagnoses—in violation of the Controlled Substances Act.
Due to this high-profile investigation, it seems likely safety and legal concerns will shape digital health clinical testing moving forward. Many of these concerns are looked into by professional groups, including the Digital Therapeutics Alliance.
DTx requires more rigorous evidence of efficacy than a telehealth app. So this barrier to entry will weed other digital health players looking to enter the market.
Artificial Intelligence in DTx
The evolution of artificial intelligence is driving a significant portion of the DTx market. In digital therapeutics, AI can be categorized in three modes:
- Analytics
- Robotic Process Automation (RPA)
- Machine learning
All three categories can cultivate or support advances in diagnosis and personalized treatment. Most digital therapeutics examples currently undergoing trials use AI to some degree.
AI-Driven Analytics
AI-driven analytics is fueled by big data—extremely large or continually updating datasets. Emerging artificial intelligence tools can process this data to perform predictive analytics.
This type of analytics has a range of DTx applications. For instance, researchers are investigating how AI trained to analyze and categorize sound might support the next generation of hearing aids.
Today, conventional hearing aids simply raise the volume for the wearer. But, AI-driven digital hearing aids could improve the wearer’s auditory processing.
The predictive software could make it easier for the wearer to separate language from background noise and understand speech.
AI-driven analytics can also draw conclusions from information in the form of medical imaging. Already, analytics programs have enhanced and expedited the analysis of brain tumors and cancer diagnoses.
Robotic Process Automation (RPA)
Robotic processing automation (RPA) automates repetitive virtual tasks. Some engineers refer to RPA as “software robotics.”
By integrating RPA into software applications, future DTx programs can streamline much of the paperwork involved in personalized treatment plans. Recent research demonstrates the promise of DTx products with significant automation.
While not all treatment processes can be automated, improved RPA technology enables human practitioners to focus more of their time on nuanced, personalized treatment work.
Machine Learning
Machine learning is a sophisticated form of AI. Once trained, ML systems can work more independently than other AI programs.
Increasingly, developers use ML programs to predict and generate new drug treatment options. Engineers will also likely utilize ML applications to support new decision support and medical device processes.
Advances in Clinical Decision Support
The second major pillar of DTx is clinical decision support. These programs improve the rate of accurate diagnoses and effective treatment plans, both in hospitals and in outpatient settings.
Clinical decision support tools may use AI programs to create predictive models from large datasets. They may also get more comprehensive and accurate data from individual patients.
Current experiments with wearable DTx devices may empower patients with chronic conditions to record experiences throughout the day. At the same time, they gather quantitative data. Clinicians can use this data to effectively adjust a treatment plan in response to the patient’s day-to-day life.
Smarter Medical Devices, Implants
Smart medical devices and implants personalize treatment. Some DTx devices monitor a patient’s biometrics. Then, they administer appropriate doses of a drug or therapy in response.
Others encourage treatment adherence by tailoring messaging to each individual patient.
Biometric Monitoring, Response
Devices that monitor a patient’s biometrics could respond to acute changes with alerts—or even with automatic medication dosing.
A new smart insulin patch is designed to effectively, and automatically administer doses of insulin in response to drops in blood glucose levels. Clinical trials are ongoing.
Another proposed connected device is a smart inhaler. It aims to use biometric readings to determine if the medication is improving the patient’s respiratory function.
A recent study of a rapid blood pressure control device improved patients’ outcomes to a clinically significant degree. The DTx device incorporated machine learning algorithms to predict and respond to patient behavior.
Personalized Treatment, Improved Adherence
DTx devices may improve patient adherence to treatment. They may also improve personalized treatment options.
Personalized treatment options may result from advanced analytics of biometric data. A patient with biomarkers that indicate specific autoimmune diseases may be eligible for targeted treatments.
Moreover, DTx devices may increase treatment adherence. Smart devices may detect if a patient misses a dose of medication and alert them. Or, it can offer pro-adherence encouragement tailored to their lifestyle.
Gamified and VR Therapy
The fourth avenue for DTx is VR technology and therapeutic games. In 2020, researchers ran a pilot study of a VR program designed to treat chronic pain.
While the final results will be published in June 2022, developers are tentatively optimistic. Virtual environments can shift patients’ perceptions of their own bodies or minds.
And a game can reward regular engagement with physical or mental therapy in a way reality may not. By tapping into the human brain’s “neurological reward mechanisms,” therapeutic game developers aim to treat illnesses with games.
JP Boyle & Associates performs executive recruitment for companies developing digital therapeutics products and solutions.
Digital Healthcare has never been more complex. So sophisticated strategies and tactics must be employed to win the battle for top talent.
We help DTx clients grow by utilizing these strategies and tactics to bring highly coveted talent to the table that can make a measurable impact on your growth and expansion.
8 Executive Skills Required for DTx Success
To capitalize on the evolving digital therapeutics landscape, executives need skills beyond traditional healthcare or tech leadership.
1. Regulatory Navigation and Compliance Leadership
Strategic Regulatory Thinking: Executives must grasp FDA approval processes, clinical trial design, and DTx regulatory pathways, including the FDA’s Digital Health Center of Excellence and the Pre-Cert Program.
Risk Management Expertise: Leaders need to balance innovation speed with compliance, as shortcuts can lead to legal and financial issues, evidenced by recent DOJ telehealth investigations.
Cross-Functional Regulatory Integration: Successful DTx executives embed regulatory considerations throughout product development, making compliance a competitive advantage.
2. Clinical Evidence and Data Science Leadership
Evidence-Based Decision Making: Executives must understand clinical trial design, biostatistics, and evidence generation for DTx, including real-world evidence collection to meet regulatory and market needs.
Data Strategy and Analytics: Leaders require expertise in big data analytics, healthcare machine learning, and translating data insights into business strategies.
Clinical Partnership Development: Executives build relationships with key opinion leaders, clinical researchers, and institutions to conduct trials and generate evidence
3. Technology Integration and Innovation Management
AI and Machine Learning Strategy:Executives must understand AI’s practical uses and limits in healthcare, including evaluating vendors, assessing bias, and ensuring AI brings real clinical value.
Interoperability and Integration Planning:Leaders need expertise in healthcare IT and electronic health records integration, navigating technical challenges in deploying DTx solutions within existing infrastructure for seamless data flow.
Cybersecurity and Data Privacy Leadership:Due to the sensitivity of health data, executives must prioritize strong cybersecurity and HIPAA compliance alongside international privacy regulations, maintaining innovation without compromising data security.
4. Market Access and Commercialization Strategy
Payer Relations and Health Economics: Successful DTx executives grasp health economics and value-based care models, articulating clear value propositions that resonate with clinical teams and economic stakeholders.
Provider Adoption Strategy: Leaders understand healthcare provider workflows and change management, identifying factors driving clinical adoption and addressing resistance proactively.
Patient Engagement and User Experience: Executives need expertise in consumer health technology to design engaging, accessible digital experiences, aiming to drive patient adherence and deliver measurable outcomes.
5. Strategic Partnership and Ecosystem Development
Pharmaceutical Partnership Strategy: Successful DTx companies partner with pharmaceutical firms to enhance therapies and patient outcomes, with executives structuring these partnerships while protecting strategic interests.
Healthcare System Integration: Leaders work effectively with large healthcare systems, understanding procurement processes, clinical integration, and change management needs.
Technology Vendor Management: Executives build and manage relationships with cloud providers, AI vendors, and tech partners, maintaining strategic control over core IP while leveraging external expertise.
6. Financial Management and Investment Strategy
DTx-Specific Financial Modeling: Executives must grasp the unique financial aspects of DTx businesses, including development timelines, regulatory costs, and digital health reimbursement economics.
Investment and Fundraising Strategy: Leaders communicate complex DTx value propositions to investors, understanding the opportunities and risks concerning healthcare-focused venture capital and strategic investors.
Revenue Model Innovation: Successful executives explore diverse revenue models, from fee-for-service to value-based contracts and subscriptions, adapting to the evolving healthcare payment landscape.
7. Organizational Development and Talent Management
Cross-Functional Team Leadership: DTx companies need clinical, regulatory, technical, and commercial expertise. Executives must build and lead diverse teams while breaking down silos between these disciplines.
Clinical and Technical Talent Acquisition: Leaders must recruit specialized talent, including clinical researchers, regulatory professionals, AI engineers, and digital health managers familiar with healthcare technology nuances.
Culture of Innovation and Compliance: Executives foster cultures balancing innovation with clinical and regulatory standards, ensuring teams see speed and safety as essential.
8. Global Market Strategy and Expansion
International Regulatory Strategy: As DTx markets grow, executives must navigate regulatory pathways in key markets like the EU and Asia-Pacific.
Cultural Adaptation and Localization: Leaders adapt DTx solutions for different healthcare systems and cultural contexts while maintaining efficacy and outcomes.
Global Partnership Development: Executives forge international partnerships with local providers, regulatory consultants, and distributors for sustainable expansion.
Building Executive Capabilities for DTx Success
Continuous Learning and Industry Engagement
The rapid change in digital therapeutics requires executives to engage in continuous learning, participate in professional organizations, attend key conferences, and stay informed on technologies and regulations.
Cross-Industry Experience Integration
Successful DTx executives often have experience from multiple industries, combining healthcare knowledge with technology, pharmaceuticals with consumer products, or regulatory affairs with venture capital. This cross-pollination is crucial for navigating the complex DTx landscape.
Advisory Board and Mentor Network Development
Due to DTx leadership’s specialized nature, executives build advisory networks with clinical experts, regulatory specialists, technology leaders, and experienced DTx entrepreneurs, providing guidance for complex decisions and market challenges.
The Future DTx Executive Profile
As the digital therapeutics market rapidly grows, demand for skilled executives will intensify. Organizations investing in these capabilities through development, hiring, or advisory relationships will best capitalize on future opportunities.
The convergence of AI, clinical decision support, smart devices, and immersive therapies offers unprecedented opportunities to improve patient outcomes and build sustainable businesses. Success requires more than innovation—it demands leadership to navigate regulations, build evidence, manage partnerships, and scale organizations in a challenging sector.
The future belongs to DTx leaders who balance innovation and compliance, speed and safety, and technological and clinical practicality. As JP Boyle & Associates states, “Digital healthcare has never been more complex. Sophisticated strategies and tactics must be employed to win the battle for top talent.” Executives who master these requirements will drive the next wave of DTx innovation, shaping the future of healthcare for millions.
The digital therapeutics revolution isn’t just about technology—it’s about leadership. Organizations recognizing this and investing in the right talent will define the next chapter of healthcare innovation.
Experienced executive search & digital therapeutics specialists. We connect top talent with innovative technologies for enhanced leadership. Explore our expertise
